原发性肝癌体部立体定向放射治疗的疗效及安全性

Efficacy and safety of stereotactic body radiation therapy for hepatocellular carcinoma

原发性肝细胞肝癌(hepatocellular carcinoma,HCC)为临床上常见的恶性肿瘤之一,外科手术为首选的治疗方法,但也存在着一定局限性。近年来,随着计算机技术和放疗设备的进步,为放疗在肝癌治疗应用方面提供了新的机会。放射治疗适应症已经从单纯姑息治疗扩展到治愈治疗。其中,体部立体定向放射治疗(stereotactic body raditiontherapy,SBRT)对于不适合一线手术或经皮射频消融的肝癌患者,在提高局部控制率和总生存率方面发挥了重要作用。SBRT的研究已经开展了很多,也获得了明确的疗效。但关于治疗肝癌的最佳剂量模式和根治性剂量的高低都需要进一步探索。本文综述SBRT对于不可手术的原发性肝癌患者的有效性、安全性及剂量分隔模式。

Hepatocellular carcinoma(HCC) is one of the most common maniglant tumours clinically.Surgery is the preferred treatment, but there are some limitations. In recent years, with the advancement in computer technology and radiotherapy equipment, it provides a new opportunity for radiotherapy in the treatment of liver cancer. Radiation therapy indications have been extended from palliative treatment to cure. Stereotactic body raditiontherapy(SBRT) has been critical in improving local control rate and overall survival rate in liver lesions not amenable to first-line surgical resection or radiofrequency ablation. Active investigations of SBRT have recently started, yielding promising local control rates. However, the optimal doses of liver cancer and liver cancer radical dose need to be further explored. Herein, this review discussed the efficacy, safety and optimal doses of SBRT in non-surgical patients with HCC.